[Guidelines on the management of ascites and complications in cirrhosis].

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. [Guidelines on the management of ascites in cirrhosis (2023 version)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023
   Guideline
2. Chinese guidelines on management of hepatic encephalopathy in cirrhosis.World journal of gastroenterology · 2019
   Guideline
3. Integrated analysis of gut microbiota structure and metabolic function in patients with cirrhosis and refractory ascites.Biomedical reports · 2026
   Article
4. Comparison of different nutritional screening tools in nutritional screening of patients with cirrhosis: A cross-sectional observational study.Heliyon · 2024
   Article
5. [Cirrhosis recompensation: clinical complications].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023
   Article
6. [Recompensation of complications in patients with hepatitis B virus-related decompensated cirrhosis treated with entecavir antiviral therapy].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023
   Article
7. [Rifaximin improves clinical symptoms and short-term survival in cirrhotic patients with refractory type ascites].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
   Article
8. [Clinical study of heparin anticoagulation scheme during plasma adsorption therapy for liver failure].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
   Article
9. [The clinical value of von Willebrand factor and VITRO score in evaluating disease progression in patients with HBV infection].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
   Article
10. Practice guidance for the use of terlipressin for liver cirrhosis-related complications.Therapeutic advances in gastroenterology · 2022
    Article
11. [Analysis of prognosis-related factors in patients with hepatitis B virus-related acute-on-chronic liver failure].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021
    Article
12. [Pathogenic bacteria characteristics and antimicrobial treatment plan for liver cirrhosis combined with spontaneous bacterial peritonitis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021
    Article
13. Effects of transjugular intrahepatic portosystemic shunt using the Viatorr stent on hepatic reserve function in patients with cirrhosis.World journal of clinical cases · 2021
    Article
14. [Present situation and prospect of diagnosis and treatment of rare complications of liver cirrhosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2020
    Article
15. [Diagnosis and treatment of rare complications of liver cirrhosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2020
    Article
16. [Clinical characteristics of infection-induced acute renal injury in acute-on-chronic liver failure].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2020
    Article
17. Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study.World journal of gastroenterology · 2020
    Observational
18. [Research progress of terlipressin in the treatment of cirrhotic ascites-related complications].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2019
    Review
19. [Reversal of cirrhotic decompensation: re-compensation].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2019
    Article
20. [Predictive value of the third lumbar skeletal muscle mass index on prognosis of patients with cirrhosis and ascites].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2019
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as